NasdaqGS:ORICBiotechs
How ORIC’s Global Phase 3 Rinzimetostat Trial with Bayer’s NUBEQA Has Changed Its Investment Story (ORIC)
ORIC Pharmaceuticals has already initiated the Himalayas-1 global Phase 3 registrational trial of rinzimetostat plus Bayer’s NUBEQA (darolutamide) in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone, enrolling around 600 participants across more than 250 sites in 25 countries.
An interesting aspect of the collaboration is that Bayer supplies darolutamide at no cost while ORIC retains full global development and commercial rights to...